ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0820

Thrombocytopenia Predicts Mortality in Chinese Hemodialysis Patients: An Analysis of the China DOPPS

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Zhao, Xinju, Peking University People's Hospital, Beijing, China
  • Niu, Qingyu, Peking University People's Hospital, Beijing, China
  • Gan, Liangying, Peking University People's Hospital, Beijing, China
  • Hou, Fan Fan, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
  • Liang, Xinling, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
  • Ni, Zhaohui, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China
  • Chen, Xiaonong, Ruijin Hospital AmMed Cancer Center Shanghai, Shanghai, Shanghai, China
  • Chen, Yuqing, Peking University First Hospital, Beijing, Beijing, China
  • McCullough, Keith, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Zuo, Li, Peking University People's Hospital, Beijing, China
Background

Mortality rate was high in Hemodialysis (HD) patients. Our previous study suggested platelet counts might be a potential risk factor. However, few studies have examined the association of platelet count with mortality in HD patients. The aim is to examine if there is an association of thrombocytopenia (TP) with mortality and cardiovascular (CV) death in Chinese HD patients.

Methods

China DOPPS5 data was used. Fifty-eight of 1427 patients were excluded for missing platelet records. Demographic data, comorbidities, lab data, and death records were extracted. Participants were divided into 2 groups according to their platelet counts as TP group( platelet<100*10^9), and Non-TP group (platelet >=100*10^9). The Non-TP could not be further divided into normal or above normal groups as limited by the sample size. Associations between platelet counts and all-cause and CV mortality were analyzed using Cox regression models. Stepwise multivariate logistic regression was used to identify related impact factors.

Results

Of 1369 patients, 201(14.7%) died and 102 (7.5%) died from CV disease. 11.2% (154) had TP at baseline. The mortality rates were 26.0% vs. 13.3% (p <0.01) in patients with and without TP. TP was associated with higher all-cause mortality after adjusted for covariates (HR:1.75, 95% CI: 1.12- 2.74), but was not associated with CV death after fully adjusted (HR: 1.75, 95% CI: 0. 89, 3.45, Figure 1). Multivariate logistic regression showed that Urine output <200 ml/day, cerebrovascular disease, hepatitis (B or C), and white blood cells were independent impact factors (P < 0.05).

Conclusion

Baseline TP is associated with higher risk of all-cause mortality in HD patients. Platelet counts may be used as early available outcome predictors among HD patients, though additional study is needed.

Funding

  • Government Support – Non-U.S.